[14]REGAN M M, FRANCIS P A, PAGANI O, et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapy for premenopausal women with HR+ HER2-negative breast cancer: results from TEXT and SOFT[J]. J Clin Oncol, 2018, 36(suppl 15): 503-503. [15]LAMBERTINI ...
2023 CSC0乳腺癌诊疗指南指出:针对高复发风险的HR+,HER2-早期乳腺癌患者遵医嘱进行术后辅助化疗、辅助放疗、辅助强化内分泌治疗等方式可进一步降低复发风险[2]。 只有武器还不够 自我管理很关键 HR+,HER2-乳腺癌的治疗是一个综合性的过...
2024年9月,美国临床肿瘤学会(ASCO)的官方期刊Journal of Clinical Oncology发表了题为“Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted T...
目前主要根据肿瘤的激素受体(hormone receptor, HR)和人表皮生长因子受体-2(Human Epidermal GrowthFactor Receptor 2, HER2)的状态进行治疗。其中HR阳性/HER2阴性(HR+/HER2-)乳腺癌是最常见的类型,占所有乳腺癌的三分之二。研究表明,使用靶向疗法,可以有效改善HR+/HER2-乳腺癌。但靶向药物和不同生物标志物的生物...
日前,复旦大学附属肿瘤医院邵志敏教授团队在 Nature Genetics 发表研究报告「Molecular classification of hormone receptor-positive HER2-negative breast cancer」,公布了 HR+/HER2-乳腺癌的复旦分型。通过多组学分析,将 HR+/HER2-乳腺癌进一步细分为 4 种亚型。这 4 种亚型在生物学行为、临床特征上存在一定差异,相应...
[2]Sheffield, Kristin M et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future oncology (London, England) vol. 18,21 (2022): 2667-2682.
[4].Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, et al. Firstline treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positivemetastatic breast cancer from registHER. Oncologist 2013;18:501–10.[5].Rimawi M, Ferrero JM, de la ...
[1]Park L, Jhaveri K, Cambron-Mellott MJ, et al. Perceptions and behaviors of US oncologists treating HR-positive HER2-negative metastatic breast cancer in second-line. 2024 SABCS. P5-01-08. [2]Turner NC, Oliveira M, Howell SJ, et al. CAPItello-291 Study Group. Capivasertib in Horm...
[2]Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEJM [3]Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (...
【2】Loibl S, Marmé F, Martin M, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial[J]. Journal of Clinical Oncology, 2021, 39(14): 1518-1530. 【3】Martin M, Hegg R, Kim S B, et al. Treatment with adjuvant...